Results 21 to 30 of about 694 (96)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

BMC Cancer, 2022
Background Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs.
Patrick Schöffski, Suzanne George, Michael C. Heinrich, John R. Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren   +17 more
doaj   +1 more source

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study

Frontiers in Oncology, 2023
IntroductionMutations in KIT proto-oncogene, receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor-α (PDGFRA) render the available tyrosine kinase inhibitors (TKI) ineffective in treating advanced gastrointestinal stromal tumors ...
Weili Yang, Haoran Qian, Litao Yang, Pengfei Wang, Hailong Qian, Binbin Chu, Zhuo Liu, Jingyu Sun, Dan Wu, Lifeng Sun, Wenqiang Zhou, Jingwei Hu, Xiaolei Chen, Chunhui Shou, Lingxiang Ruan, Yunyun Zhang, Jiren Yu   +16 more
doaj   +1 more source

Ripretinib: A narrative drug review

Cancer Research, Statistics, and Treatment, 2021
Gastrointestinal stromal tumors (GISTs) are rare primary neoplasms of the gastrointestinal tract, mesentery, or omentum. In the past, for patients with resectable tumors, surgery was the only viable treatment option.
Silpa S Kumar, Arun Philip, Keechilat Pavithran   +2 more
doaj   +1 more source

Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis

Cancer Medicine, 2023
Background Imatinib is the standard first‐line treatment for advanced gastrointestinal stromal tumors (GISTs); however, most patients eventually develop imatinib resistance, leading to considerable clinical challenges.
Kehan Hu, Hu Zhang, Mingrong Shu, Xingyue Wang   +3 more
doaj   +1 more source

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique

Drug Design, Development and Therapy, 2021
Hui-jun Wang,1 Chun-yan Zhou,1 Yan-ding Su,1 Kai-feng Gou,1 Xiao-nan Geng,1 Xiang-jun Qiu1,2 1Department of Pharmacy, School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, 471023, People’s Republic of China; 2Functional ...
Wang H, Zhou C, Su Y, Gou K, Geng X, Qiu X   +5 more
doaj  

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward

Therapeutic Advances in Medical Oncology, 2021
Gastrointestinal stromal tumor (GIST) represents a paradigm for clinically effective targeted inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the standard of care for the treatment of advanced or metastatic GIST
M. Julia Lostes-Bardaji, David García-Illescas, Claudia Valverde, César Serrano   +3 more
doaj   +1 more source

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

Frontiers in Oncology, 2021
The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine kinase inhibitor (TKI), meaningfully improved the treatment of ...
Sebastian Bauer, Suzanne George, Margaret von Mehren, Michael C. Heinrich   +3 more
doaj   +1 more source

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors

Frontiers in Oncology, 2022
Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have a different pathogenesis, clinical characteristics, and treatment response ...
Yingchao Sun, Lei Yue, Pengfu Xu, Weiling Hu, Weiling Hu, Weiling Hu   +5 more
doaj   +1 more source

A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor

Frontiers in Pharmacology, 2022
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic gastrointestinal stromal tumors (GISTs) in the last two decades.
Xianhao Xiao, Weiye Yuan, Chong Wang, He Song   +3 more
doaj   +1 more source

Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India

Future Science OA, 2021
The therapeutic landscape in advanced gastrointestinal stromal tumor has evolved. Avapritinib and ripretinib have now been approved by the US FDA for platelet-derived growth factor alpha D842V-mutant and refractory gastrointestinal stromal tumor patients,
Saurav Verma, Rohit Reddy, Sheragaru Hanumanthappa Chandrashekhara, Shamim Ahmed Shamim, Sarthak Tripathy, Sameer Rastogi   +5 more
doaj   +1 more source